David A. Roth
2020 - Syros Pharmaceuticals
In 2020, David A. Roth earned a total compensation of $1.2M as Chief Medical Officer at Syros Pharmaceuticals, a 26% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $244,400 |
|---|---|
| Option Awards | $480,697 |
| Salary | $468,269 |
| Other | $360 |
| Total | $1,193,726 |
Roth received $480.7K in option awards, accounting for 40% of the total pay in 2020.
Roth also received $244.4K in non-equity incentive plan, $468.3K in salary and $360 in other compensation.
Rankings
In 2020, David A. Roth's compensation ranked 7,860th out of 13,090 executives tracked by ExecPay. In other words, Roth earned more than 40.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,860 out of 13,090 | 40th |
Division Manufacturing | 3,325 out of 5,620 | 41st |
Major group Chemicals And Allied Products | 1,348 out of 2,253 | 40th |
Industry group Drugs | 1,170 out of 1,953 | 40th |
Industry Pharmaceutical Preparations | 872 out of 1,458 | 40th |
Source: SEC filing on April 29, 2021.
Roth's colleagues
We found two more compensation records of executives who worked with David A. Roth at Syros Pharmaceuticals in 2020.
News
Syros Pharmaceuticals CEO Nancy Simonian's 2022 pay rises 12% to $3.5M
April 21, 2023
Syros Pharmaceuticals CEO Nancy Simonian's 2021 pay jumps 23% to $3.1M
April 21, 2022
Syros Pharmaceuticals CEO Nancy Simonian's 2020 pay falls 30% to $2.5M
April 29, 2021
Syros Pharmaceuticals CEO Nancy Simonian's 2019 pay rises 19% to $3.6M
April 28, 2020
Syros Pharmaceuticals CEO Nancy Simonian's 2018 pay jumps 36% to $3M
April 25, 2019